Ulixertinib
CAS No. 869886-67-9
Ulixertinib( BVD-523 | VRT752271 )
Catalog No. M17630 CAS No. 869886-67-9
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 31 | In Stock |
|
5MG | 50 | In Stock |
|
10MG | 80 | In Stock |
|
25MG | 129 | In Stock |
|
50MG | 177 | In Stock |
|
100MG | 335 | In Stock |
|
200MG | 484 | In Stock |
|
500MG | 771 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUlixertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionUlixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
-
DescriptionUlixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
-
In Vitro——
-
In Vivo——
-
SynonymsBVD-523 | VRT752271
-
PathwayOthers
-
TargetOther Targets
-
RecptorERK2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number869886-67-9
-
Formula Weight433.33
-
Molecular FormulaC21H22Cl2N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 45 mg/mL; 103.85 mM
-
SMILES[nH]1c(cc(c1)c1cc(ncc1Cl)NC(C)C)C(=O)N[C@H](CO)c1cc(ccc1)Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ward RA, et al. J Med Chem. 2015, 58(11), 4790-4801.
molnova catalog
related products
-
CCP peptide
CCP peptide is a synthetic cyclic peptide incorporating the amino acid citrulline.
-
Toyocamycin
Toyocamycin is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM).
-
Peptide C105Y
C105Y, a synthetic peptide (CSIPPEVKFNKPFVYLI) based on the amino acid sequence corresponding to residues 359-374 of alpha1-antitrypsin, enhances gene expression from DNA nanoparticles.